Last reviewed · How we verify

EXPAREL and bupivacaine HCl

Pacira Pharmaceuticals, Inc · FDA-approved active Small molecule

EXPAREL is a liposomal formulation of bupivacaine that provides prolonged local anesthesia by slowly releasing bupivacaine from lipid vesicles to block sodium channels in nerve fibers.

EXPAREL is a liposomal formulation of bupivacaine that provides prolonged local anesthesia by slowly releasing bupivacaine from lipid vesicles to block sodium channels in nerve fibers. Used for Infiltration anesthesia and nerve block in adults for surgical anesthesia and postoperative analgesia, Interscalene brachial plexus nerve block for postoperative analgesia.

At a glance

Generic nameEXPAREL and bupivacaine HCl
SponsorPacira Pharmaceuticals, Inc
Drug classLocal anesthetic (liposomal formulation)
TargetVoltage-gated sodium channels
ModalitySmall molecule
Therapeutic areaPain Management / Anesthesia
PhaseFDA-approved

Mechanism of action

Bupivacaine is a local anesthetic that works by inhibiting sodium influx through sodium-selective ion channels in the nerve cell membrane, thereby blocking the initiation and conduction of nerve impulses. EXPAREL encapsulates bupivacaine in liposomes, which extend the duration of anesthesia from hours to up to 72 hours by providing sustained release of the active drug at the injection site. This allows for prolonged postoperative pain control without repeated dosing.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results